Adebrelimab
- Generic Name
- Adebrelimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2247114-85-6
- Unique Ingredient Identifier
- 1XBY50W1OX
- Background
Adebrelimab is under investigation in clinical trial NCT03711305 (Study of Carboplatin Plus Etoposide With or Without SHR-1316 in Participants With Untreated Extensive-stage (ES) Small Cell Lung Cancer (SCLC)).
- Indication
用于与卡铂和依托泊苷联合用于广泛期小细胞肺癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06225921
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
Neoadjuvant Therapy of HAIC（GEMOX） Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
- Conditions
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-11-20
- Target Recruit Count
- 33
- Registration Number
- NCT06208462
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract Malignancies
- Conditions
- Interventions
- First Posted Date
- 2023-12-26
- Last Posted Date
- 2024-04-30
- Target Recruit Count
- 35
- Registration Number
- NCT06181032
- Locations
- 🇨🇳
The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian, China
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 30
- Registration Number
- NCT06177522
- Locations
- 🇨🇳
Wang Sizhen, Nanjing, Jiangsu, China
A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC
- Conditions
- Interventions
- First Posted Date
- 2023-12-20
- Last Posted Date
- 2023-12-20
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 62
- Registration Number
- NCT06177925
- Locations
- 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, China
Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Adenocarcino
- Conditions
- Interventions
- First Posted Date
- 2023-12-05
- Last Posted Date
- 2023-12-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT06156267
- Locations
- 🇨🇳
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University, Shanghai, Shanghai, China
Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy in Cervical Cancer
- First Posted Date
- 2023-11-29
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT06149767
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR+/HER2 - Advanced Breast Cancer
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 82
- Registration Number
- NCT06149130
- Locations
- 🇨🇳
Tongji Hospital Affiliated of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-10-19
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT06091124
- Locations
- 🇨🇳
Ren Ji Hospital, Shanghai, Shanghai, China
Hepatic Artery Infusion of Adebrelimab Combined With Bevacizumab in the Treatment of Advanced Hepatocellular Carcinoma With Failure of Systemic Therapy Combined With Interventional Therapy
- Conditions
- Interventions
- First Posted Date
- 2023-08-04
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- HuiKai Li
- Target Recruit Count
- 30
- Registration Number
- NCT05975463
- Locations
- 🇨🇳
Tianjin Cancer Hospital Airport Hospital, Tianjin, Tianjin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.